Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Non-Current Assets (2019 - 2026)

Enliven Therapeutics has reported Non-Current Assets over the past 8 years, most recently at $1.7 million for Q1 2026.

  • Quarterly results put Non-Current Assets at $1.7 million for Q1 2026, down 79.22% from a year ago — trailing twelve months through Mar 2026 was $19.5 million (down 41.44% YoY), and the annual figure for FY2025 was $1.3 million, down 83.1%.
  • Non-Current Assets reached $1.7 million in Q1 2026 per ELVN's latest filing, up from $1.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $8.9 million in Q2 2024 and bottomed at $410000.0 in Q2 2022.
  • Median Non-Current Assets over the past 5 years was $5.6 million (2022), compared with a mean of $5.5 million.
  • The largest annual shift saw Non-Current Assets skyrocketed 1199.02% in 2023 before it crashed 83.1% in 2025.
  • Over 5 years, Non-Current Assets stood at $5.5 million in 2022, then grew by 3.08% to $5.7 million in 2023, then surged by 33.54% to $7.6 million in 2024, then plummeted by 83.1% to $1.3 million in 2025, then surged by 32.95% to $1.7 million in 2026.
  • Business Quant data shows Non-Current Assets for ELVN at $1.7 million in Q1 2026, $1.3 million in Q4 2025, and $8.2 million in Q3 2025.